Strategic Market POV
The Seronegative Myasthenia Gravis Market
A market intelligence & strategy POV ahead of a probable VYVGART label expansion.
Featured Report
Where a structurally excluded patient population finally gets a label.
SNMG patients have spent a decade reading about category breakthroughs that were not for them. With VYVGART's expected label expansion in May 2026, the question is no longer "why this therapy" — it's "why now, for an audience that has been waiting." This POV synthesizes peer-reviewed evidence, FDA-regulated sources, and direct patient voice into the five gaps that should shape creative, channel, and clinician-facing strategy.
Inside the report
- Five market gaps grounded in peer-reviewed data — including a 1.46-fold higher MG-ADL burden in SNMG vs. AChR+ patients (Lehnerer 2025, n=237)
- Direct patient voice from r/MyastheniaGravis — the FND detour, the magnesium trap, and how patients teach each other to find diagnosis
- Audience-specific activation: how to position a brand as recognition, not just efficacy, when the label language has been the structural exclusion
Get the full report
Brief form to access — sent to your inbox